<DOC>
	<DOCNO>NCT02845037</DOCNO>
	<brief_summary>The purpose study assess safety tolerability BIA 5-453 single oral dos</brief_summary>
	<brief_title>Tolerability , Pharmacokinetics Dopamine ß-hydroxylase ( DßH ) Inhibition Profile BIA 5-453</brief_title>
	<detailed_description>Single centre , randomise , double-blind , placebo-controlled study single ascending dose 10 sequential group 8 healthy young male volunteer . Within group ( n=8 ) , 6 volunteer randomise receive BIA 5-453 remain 2 volunteer randomise receive placebo . A volunteer participate single period .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<criteria>1 . A signed date informed consent form studyspecific screen procedure perform . 2 . Aged 18 45 year , inclusive . 3 . Healthy determine investigator basis medical history , physical examination , clinical laboratory test result , vital sign digital 12lead electrocardiogram ( ECG ) . 4 . Nonsmoker smoker few 10 cigarette per day determine history . Must able abstain smoking inpatient stay . 5 . Have high probability compliance completion study . Medical History 1 . Any significant cardiovascular ( e.g . hypertension ) , hepatic , renal , respiratory ( e.g . childhood asthma ) , gastrointestinal , endocrine ( e.g . diabetes , dyslipidemia ) , immunologic , dermatological , haematological , neurologic , psychiatric disease . 2 . Acute disease state ( e.g. , nausea , vomit , fever , diarrhoea ) within 7 day study day 1 . 3 . History drug abuse within 1 year study day 1 . 4 . History alcoholism within 1 year day 1 . Consumption 50 g ethanol per day ( 12.5 cL glass 10° [ 10 % ] wine = 12 g ; 4 cL aperitif , 42° [ 42 % ] whiskey = 17 g ; 25 cL glass 3° [ 3 % ] beer = 7.5 g ; 25 cL glass 6° [ 6 % ] beer = 15 g 5 . History clinically important drug allergy . Physical Laboratory Findings 6 . An automatic ECG QTc interval read screen enrolment &gt; 450 ms. 7 . Positive serologic finding human immunodeficiency virus ( HIV ) antibody , hepatitis B surface antigen ( HBsAg ) , and/or hepatitis C virus ( HCV ) antibody . 8 . Positive finding urine drug screen ( eg , amphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine , methadone , opiates , MDMA [ 3,4methylenedioxymethamphetamine ; ecstasy ] ) . Prohibited treatment 9 . Prohibited Treatments : use investigational drug within 90 day prescription drug within 30 day investigational medical product ( IMP ) administration . 10 . Consumption caffeinecontaining product ( e.g. , coffee , tea , chocolate , soda ) excess 6 cup per day ( equivalent ) , grapefruit , grapefruitcontaining product , alcoholic beverage within 72 study day 1 . 11 . Use overthecounter drug include herbal supplement ( except occasional use acetaminophen [ paracetamol ] , aspirin vitamin ≤100 % recommend daily allowance ) within 7 day IMP administration . 12 . Donation blood ( ie 450 ml ) within 90 day study day 1 .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>